- Home
- GLPG vs IRON Comparison
GLPG vs IRON Comparison
Compare GLPG & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- IRON
- Stock Information
- Founded
- GLPG 1999
- IRON 2017
- Country
- GLPG Belgium
- IRON United States
- Employees
- GLPG N/A
- IRON N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- GLPG Health Care
- IRON Health Care
- Exchange
- GLPG Nasdaq
- IRON Nasdaq
- Market Cap
- GLPG 2.1B
- IRON 2.1B
- IPO Year
- GLPG 2005
- IRON N/A
- Fundamental
- Price
- GLPG $32.02
- IRON $59.82
- Analyst Decision
- GLPG Sell
- IRON Strong Buy
- Analyst Count
- GLPG 4
- IRON 10
- Target Price
- GLPG $25.33
- IRON $97.80
- AVG Volume (30 Days)
- GLPG 198.2K
- IRON 288.5K
- Earning Date
- GLPG 10-29-2025
- IRON 11-11-2025
- Dividend Yield
- GLPG N/A
- IRON N/A
- EPS Growth
- GLPG N/A
- IRON N/A
- EPS
- GLPG N/A
- IRON N/A
- Revenue
- GLPG $323,674,692.00
- IRON N/A
- Revenue This Year
- GLPG N/A
- IRON N/A
- Revenue Next Year
- GLPG N/A
- IRON N/A
- P/E Ratio
- GLPG N/A
- IRON N/A
- Revenue Growth
- GLPG 5.43
- IRON N/A
- 52 Week Low
- GLPG $22.36
- IRON $30.82
- 52 Week High
- GLPG $33.86
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- GLPG 49.28
- IRON 50.30
- Support Level
- GLPG $30.88
- IRON $58.59
- Resistance Level
- GLPG $33.63
- IRON $61.27
- Average True Range (ATR)
- GLPG 0.69
- IRON 2.13
- MACD
- GLPG -0.02
- IRON -0.15
- Stochastic Oscillator
- GLPG 41.45
- IRON 18.47
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.